According to the law firm press release, Bellicum Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for various forms of cancer.

The Company’s lead clinical product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation. Bellicum has represented that BPX-501 is currently being evaluated in multiple Phase 1/2 clinical trials.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a substantial undisclosed risk of encephalopathy was associated with the Company’s lead product candidate BPX-501; and (ii) as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.

On January 30, 2018, post-market, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States,” announcing that it had “received notice from the U.S. Food and Drug Administration that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.”

On this news, Bellicum’s share price fell $2.12, or 25.85%, to close at $6.08 on January 31, 2018.

On April 9, 2018, the Court issued an Order consolidating cases. On March 26, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on May 15. Defendants filed a Motion to Dismiss the amended Complaint on July 5. On May 29, 2020, the Court issued an Order granting Defendants' Motion to Dismiss. The case was dismissed with prejudice.